Selank
A synthetic heptapeptide analogue of tuftsin developed at the Institute of Molecular Genetics of the Russian Academy of Sciences; registered as a pharmaceutical nasal spray in Russia for anxiety and neurasthenia. Reportedly investigated for anxiolytic and nootropic effects including attention, memory, and stress response modulation. The primary evidence base is concentrated in Russian-language clinical literature; independent replication in internationally indexed journals is limited, constraining the conclusions that can be drawn.
Side effects & risks
Selank's human safety profile is limited in the scope of what can be independently verified from English-language peer-reviewed literature. The compound is a registered pharmaceutical in Russia for anxiety treatment and has been administered to patients in that context, but the majority of safety data originates from studies conducted by the Institute of Molecular Genetics of the Russian Academy of Sciences and affiliated institutions. These studies may not have been conducted under GCP standards comparable to EMA or FDA trial requirements, and independent replication by research groups outside Russia is absent for safety endpoints.
In the human studies available in English-language peer-reviewed literature, adverse event reporting is limited. Russian clinical studies (available in primary-language literature) described selank as well tolerated, with no significant adverse events reported at therapeutic doses. Importantly, those studies also reported no withdrawal symptoms following discontinuation of prescribed treatment courses — a notable finding given the theoretical benzodiazepine-pathway concern discussed below. The patient populations and full safety methodology are not evaluable from available English abstracts; the primary data is in Russian-language publications.
Community reports — predominantly from forums focused on nootropics and cognitive enhancement — describe selank as subjectively mild, with few acute adverse events at the nasal spray doses typically discussed (250 mcg to 1 mg per nostril). Reported adverse experiences include temporary fatigue post-administration and mild headache. No serious adverse events have been reported in community accounts with sufficient frequency or detail to assess causality or incidence.
A theoretical risk exists in any compound that modulates the GABAergic system or interacts with benzodiazepine receptor-related pathways. Selank's proposed mechanism includes benzodiazepine receptor modulation as one hypothesis (see mechanismSummary); if this mechanism is operative, concerns analogous to benzodiazepine-class compounds — tolerance, dependence, withdrawal — may be relevant over extended use. Russian clinical studies reportedly found no withdrawal symptoms after discontinuation of therapeutic courses; however, those studies involved short prescribed courses (up to 14 days), and the question of tolerance with prolonged or repeated use remains uncharacterised in independently verifiable peer-reviewed human trials.
Selank is not approved for any therapeutic indication by the FDA or EMA. Its Russian regulatory approval applies to a specific registered formulation within the Russian pharmaceutical system and does not extend to compounded or research-chemical versions sold in other markets.
Evidence summary
Latest studies
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
This narrative review, published in the Journal of the American Academy of Orthopaedic Surgeons: Global Research & Reviews, examines a broad class of research compounds called therapeutic peptides and asks whether they might have a role in orthopaedic medicine — including bone, tendon, muscle, and nerve recovery. Researchers reviewed the published scientific literature on several peptides, including BPC-157, TB-500, GHK-Cu, ipamorelin, CJC-1295, tesamorelin, sermorelin, semax, selank, and epitalon. Each compound was evaluated for its proposed biological mechanism and its relevance to orthopaedic injury and recovery. The review found that these peptides appear to act on molecular pathways involved in tissue repair, inflammation resolution, and nerve signalling. Wound-healing peptides such as BPC-157, TB-500, and GHK-Cu were reported to promote blood vessel formation and tissue remodelling. Growth hormone-stimulating peptides like ipamorelin, CJC-1295, tesamorelin, and sermorelin were described as activating repair-related growth signals. Peptides such as epitalon were linked to cellular energy regulation, and neuroactive peptides like semax and selank were associated with nerve growth factor pathways. However, the authors explicitly noted that clinical trials in human orthopaedic patients are currently lacking. The mechanistic evidence reviewed comes primarily from laboratory and animal studies. No adverse event data specific to this review were reported in the...
Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats.
Researchers tested Selank, a synthetic peptide with anti-anxiety properties, in rats going through morphine withdrawal triggered by a blocking drug (naloxone). A single injection of Selank reduced the overall severity of withdrawal by about 40%, notably easing convulsion-like reactions, drooping eyelids, and posture problems, and it made the animals far less sensitive to touch-based discomfort. Selank was slightly weaker than the standard anti-anxiety drug diazepam on these measures. The authors conclude Selank eased the distressing signs of opioid withdrawal in rats, much like diazepam. The abstract reports no adverse events. These are preclinical findings in rats; human studies would be needed before any clinical conclusions about Selank and withdrawal.
Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank.
This review article discusses a range of sedative and calming drugs that work through the brain's GABA system, including their medical uses and their potential for misuse. It notes that Selank, a peptide developed in Russia, is not well studied and is nonetheless sold to US consumers as a dietary supplement, which the authors flag as a concern. The article's value here is context: it presents Selank as under-researched and cautions about products marketed with little safety data. It does not report new experiments on Selank or establish its safety or benefit. This is a review offering a cautious, consumer-protection perspective rather than direct evidence about what Selank does.
Community discussion
Community-reported · not verified
These are synthesised observations from public forum discussions. They are community-reported, not clinically verified, and should not inform any health decision. The peptide does not cure, treat, or prevent any condition based on these reports.
“Feedback on combined Selank/Semax”
A user asks for feedback on running Selank and Semax together. The thread discusses reported protocols for combining the anxiolytic and nootropic peptides, including timing and whether the two are typically alternated or stacked.
“Semax and Selank come from two completely unrelated molecules. They share the same three-amino-acid tail.”
An explainer thread noting that Semax derives from an ACTH fragment while Selank derives from tuftsin, yet both carry the same Pro-Gly-Pro C-terminal tail. The discussion concerns structural origin and how the shared tail relates to stability and reported effects.
“Anyone have experience with Semax or Selank peptides?”
A user in an anhedonia support community asks whether others have experience with Semax or Selank. The thread gathers reported protocols and subjective impressions on mood and motivation from those who have used either peptide.
“Phenylpiracetem, Semax, And Selank Combo Spray”
The poster discusses a nasal spray combining phenylpiracetam, semax, and selank. The thread considers whether the combination makes sense and how users report dosing it.
“Semax Selank Protocol - need advice”
The poster asks for input on a combined semax and selank protocol. Replies cover reported dosing, timing, and cycling practices.
Reported protocols (with caveats)
| USE | ROUTE | COMMON DOSE | FREQUENCY | TYPICAL CYCLE |
|---|---|---|---|---|
| Anxiolytic (Russian approved context) | Intranasal (0.15% solution) | 200–300 mcg per nostril | 2–3× daily | 5–14 days |
| Nootropic / anxiety (community-reported, research chemical) | Intranasal | 250–500 mcg per nostril | 1–2× daily | Variable (days to weeks) |
Frequently asked questions
- Is selank approved as a drug anywhere?
- Selank is registered as a pharmaceutical product in Russia for use as an anxiolytic, where it is available as a nasal spray. It is not approved by the FDA, EMA, or the regulatory authorities of most Western markets. Its Russian approval is based on clinical studies conducted in Russia, the methodology of which is not fully reproducible from available English-language publications.
- How strong is the evidence for selank?
- The evidence is limited and concentrated in a single Russian research group. Human clinical studies described in English-language reviews report anxiolytic effects comparable to benzodiazepines with fewer sedative side effects, but the primary trial data is in Russian-language literature and cannot be independently evaluated for methodological quality. Preclinical rodent data on anxiolytic behaviour is more extensive but also primarily from the originating research group. Independent replication by external laboratories is sparse.
- What are the known risks of selank?
- Adverse event data from available English-language publications reports selank as well tolerated in the clinical studies conducted in Russia. Community reports describe selank as subjectively mild, with occasional post-administration fatigue or headache. A theoretical risk exists if selank modulates GABAergic or benzodiazepine receptor pathways — extended use could theoretically involve tolerance or dependence concerns analogous to that drug class. This has not been formally studied in peer-reviewed human trials accessible in English. The safety profile in Western research-chemical users has not been evaluated in controlled trials.
- Is selank the same as semax?
- No. Selank and semax are distinct synthetic peptides developed by the same Russian research institute, often discussed together in nootropic communities. Selank is a tuftsin analogue with proposed anxiolytic and immunomodulatory properties. Semax is an ACTH analogue with proposed cognitive-enhancement and neuroprotective properties. They have different sequences, different proposed mechanisms, and separate (though similarly limited) evidence bases.
- Is selank legal to buy or use?
- Selank is not approved by the FDA or EMA and is sold as a research chemical in most Western markets. It is a registered pharmaceutical in Russia. Regulatory status varies by country; in some jurisdictions it is unscheduled, in others it may be subject to import restrictions. Verify current regulatory status with a qualified legal or clinical professional.